Drug intelligence / Profile preview

PURR-05

Development stage: Preclinical
Lead developer: The Cat Health Company

Overview

PURR-05 is a veterinary therapeutic candidate under development by The Cat Health Company, a biotechnology firm focused on feline longevity and age-related diseases. The drug is part of a pipeline of compounds designed to treat common conditions in senior cats, specifically targeting sarcopenia (muscle wasting), chronic kidney disease (CKD), and neurodegeneration. The program aims to extend the healthy lifespan of domestic cats by addressing the underlying biological drivers of aging. While the specific molecular targets and modalities for PURR-05 have not been publicly disclosed, it represents a specialized approach to geriatric feline medicine within the company's broader aging-related portfolio.

Beyond the preview

Go deeper on PURR-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PURR-05.

Explore the full profile